The FDA has approved three immunotherapy drugs—avelumab, atezolizumab, and durvalumab—for the treatment of patients with bladder cancer. All three drugs belong to a class of cancer therapies known as checkpoint inhibitors.
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2pP0A4J
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου